Equity Vaccines prepares to launch clinical trials for groundbreaking malaria vaccine in Nigeria

Equity Vaccines Ltd., a pioneering subsidiary of the Equity Health Group, is on the verge of completing the pre-clinical stage of its innovative malaria vaccine in collaboration with a reputable university in Nigeria. This significant achievement sets the stage for the upcoming clinical trials, marking a critical milestone in the company’s ambitious plan to produce 100 million doses annually and play a transformative role in combating malaria across Nigeria and Africa.

As Nigeria continues to battle high malaria incidence rates—305 new cases per 1,000 people at risk in 2022 alone—Equity Vaccines’ initiative underscores a renewed commitment to tackling one of the continent’s most pressing public health challenges. While existing vaccines have shown promise, particularly in children, Equity Vaccines is advancing a more robust solution that aims to protect a broader population.

Under the visionary leadership of Dozy Mmobuosi, a UK-based Nigerian entrepreneur, and HRM Adeyeye Enitan Ogunwusi (Ọjájá II), the Ooni of Ife, Equity Vaccines is preparing to revolutionize malaria prevention in Nigeria. Alongside its sister subsidiaries—Equity Pharmaceuticals Ltd. and Equity Specialist Clinics & Diagnostic Centre—the company is poised to initiate clinical trials for this groundbreaking malaria vaccine.

“Our mission to combat malaria is entering a critical phase with the imminent completion of pre-clinical trials and the upcoming commencement of rigorous clinical trials across designated centers nationwide,” stated Dozy Mmobuosi, Founder and Co-owner of Equity Health Group. “We are dedicated to maintaining the highest standards of quality and safety, ensuring that our processes meet not only the stringent requirements of Nigerian regulatory bodies like NAFDAC and SON but also the global standards set by the WHO. Our ultimate goal is to make this life-saving vaccine accessible and affordable, not just in Nigeria, but across Africa.”

Dr. Preye Ogbe, Director of Research & Development at Equity Vaccines, emphasized the importance of this milestone in the broader context of vaccine innovation: “This project represents the culmination of years of rigorous research and collaboration. Our partnership with a leading Nigerian university will be instrumental in achieving this breakthrough. As we transition into the clinical phase, we are confident in the vaccine’s potential to significantly reduce the malaria burden across the continent.”

Pending final regulatory approvals, the clinical trials will mark a significant advancement for Equity Vaccines. The company is working closely with government authorities to ensure full compliance and is laying the groundwork for large-scale vaccine production. With the capacity to produce up to 100 million doses annually, Equity Vaccines is positioning itself as a key player in the global fight against malaria.

Senator Ned Nwoko, who has been a vocal advocate for Malaria Eradication in Nigeria through his foundation, has encouraged the efforts of vaccine stakeholders in Nigeria and Africa in ensuring that Nigeria is indeed self-reliant in vaccine development. “By producing vaccines and health products locally, we are reducing our dependence on foreign supplies, ensuring that Nigerians have timely access to life-saving interventions. This initiative will strengthen our public health infrastructure and contributes to the broader economic and social stability of Nigeria.”

Dr. Segun Sanni, Director of Programmes and Compliance at Equity Health Group highlighted the strategic importance of the company’s approach to vaccine distribution: “Adhering to regulatory standards and building a robust distribution network are crucial for the success of this initiative. We are collaborating with government agencies to ensure our vaccine meets international safety and efficacy standards.”

In addition to its groundbreaking work on the malaria vaccine, Equity Vaccines is actively engaged in research and development for other critical vaccines tailored to the African market. This comprehensive approach reflects the company’s broader vision of contributing to significant health advancements both within Africa and on a global scale.
As Equity Vaccines moves forward with this landmark clinical trial, the company is not just developing a vaccine; it is pioneering a new era in African healthcare. The forthcoming malaria vaccine, with the potential to save millions of lives, represents a transformative leap forward in the fight against one of the continent’s most devastating diseases.